Clinical Trial Update: A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated EZN-2968, an antisense inhibitor of HIF-1alpha, in adults with advanced solid tumors with liver metastases. The study status is Com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Metastases

Drugs mentioned

• EZN-2968

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Neoplasms, Liver Metastases | Phase 1 | Status: COMPLETED